Top Page
Living Cell Technologies
(OTC:1AI)
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
Living Cell Technologies Business Overview & Revenue Model
Living Cell Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -557.00 | -743.00 | -49.31K |
| EBITDA | -887.42K | -1.54M | -2.20M | -2.13M | -2.38M | -1.86M |
| Net Income | -150.24K | -802.96K | -2.10M | -2.11M | -1.96M | -1.46M |
Balance Sheet | ||||||
| Total Assets | 2.40M | 2.40M | 5.49M | 6.23M | 4.27M | 1.64M |
| Cash, Cash Equivalents and Short-Term Investments | 2.32M | 2.32M | 3.11M | 6.13M | 7.24M | 1.61M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 169.76K | 169.76K | 178.45K | 449.86K | 239.26K | 265.08K |
| Stockholders Equity | 2.23M | 2.23M | 3.01M | 3.76M | 4.03M | 1.38M |
Cash Flow | ||||||
| Free Cash Flow | -84.69K | -785.25K | -1.52M | -1.99M | -2.05M | -1.46M |
| Operating Cash Flow | -84.69K | -785.25K | -1.52M | -1.99M | -2.04M | -1.46M |
| Investing Cash Flow | 250.00K | 450.00K | -277.44K | 0.00 | 39.50K | 105.86K |
| Financing Cash Flow | -3.00K | -3.00K | 523.00K | 1.85M | 4.69M | -44.54K |
Living Cell Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$8.27M | -17.46 | -8.72% | ― | ― | 71.10% | |
44 Neutral | AU$38.25M | -9.13 | -16.65% | ― | ― | -672.73% | |
41 Neutral | AU$24.49M | -28.00 | -30.33% | ― | ― | ― | |
39 Underperform | AU$16.12M | -3.57 | -90.15% | ― | -93.83% | 20.00% |
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests in the company’s securities following his participation in a loyalty option offer. Hainsworth, who holds both direct and indirect stakes, acquired a total of 5,125,000 new unlisted options exercisable at $0.014 and expiring on 1 December 2029, at an issue price of $0.001 per option, increasing his exposure to the company’s equity without disposing of any existing securities, which further aligns his incentives with long‑term shareholder value.
Algorae Pharmaceuticals Limited has notified the market of the issue of 199,013,513 unquoted options, each expiring on 1 December 2029, under the ASX code 1AIAT. The options, which are not intended to be quoted on the ASX, were issued as part of previously announced transactions, signalling a significant expansion of the company’s unquoted equity base and potentially affecting capital structure and future shareholder dilution dynamics.
Algorae Pharmaceuticals Limited has applied for quotation of 1,663 new fully paid ordinary shares on the ASX, with an issue date of 19 December 2025. The small-scale share issuance, arising from the exercise or conversion of existing instruments, marginally increases the company’s quoted capital and reflects ongoing capital management activities without significantly altering its overall market position or capital structure.
Algorae Pharmaceuticals has closed its non-renounceable pro-rata loyalty options entitlement offer, receiving applications for 199,013,513 options at $0.001 each and raising approximately $199,014 before costs, with the options expected to be issued on 22 December 2025. The remaining 138,737,943 options constitute a shortfall that will be placed at the company’s discretion under a separate shortfall offer within three months, with funds from both offers earmarked for offer costs and general working capital, modestly strengthening Algorae’s balance sheet and providing incremental support for its AI-driven drug discovery and commercialisation activities.
Algorae Pharmaceuticals has announced the receipt of comprehensive in silico synergy predictions from its AI platform, AlgoraeOS v2, which evaluates over 500,000 CBD-drug-cell line combinations. The platform outperforms existing models, including those from Google DeepMind, across major synergy metrics, and has identified 90 high-quality drug combination candidates for further evaluation. The company is in discussions with the Peter MacCallum Cancer Centre for independent validation of these results, marking a significant step in its AI-driven drug discovery efforts.
Algorae Pharmaceuticals has received a cash refund of $384,466.78 from the Australian Taxation Office under the R&D Tax Incentive program for its eligible research and development activities in 2025. This non-dilutive funding will bolster the company’s financial position and support its AI-driven drug discovery programs and commercial pipeline, reflecting its commitment to innovative pharmaceutical development.
Algorae Pharmaceuticals Ltd announced successful preclinical validation of its AlgoraeOS v1 platform, which predicts synergistic drug combinations. The validation, conducted by the Victorian Centre for Functional Genomics, confirmed the platform’s ability to identify effective CBD-drug combinations, supporting its use in future drug discovery. This milestone enhances Algorae’s industry positioning by demonstrating the predictive power of its technology, potentially benefiting stakeholders through more targeted and efficient drug development processes.
Algorae Pharmaceuticals has announced the dispatch of offer documents and letters to eligible shareholders as part of its non-renounceable pro-rata entitlement offer of new options. This offer, which allows existing shareholders to acquire new shares at a specified price, has seen an increase in the number of options available due to recent exercises by option holders. The offer is open until December 15, 2025, and aims to strengthen the company’s financial position, potentially impacting its market presence and providing growth opportunities for stakeholders.
Algorae Pharmaceuticals Limited has announced a new issuance of securities, with 364,327 ordinary fully paid securities set to be quoted on the Australian Securities Exchange (ASX) under the code 1AI. This move is part of the company’s strategic financial operations, potentially impacting its market positioning and providing stakeholders with insights into its growth and expansion strategies.
Algorae Pharmaceuticals has signed a distribution agreement with Dr. Reddy’s Laboratories to supply the chemotherapy medicine Capecitabine to the Australian market, with the first shipment expected in December 2025. This strategic partnership is set to expand Algorae’s commercial footprint and provide a pathway to near-term revenue, while positioning the company for long-term growth and future collaborations in the oncology sector.
Algorae Pharmaceuticals Limited has announced a proposed issue of securities, specifically 30,000,000 options set to expire on December 1, 2029. This move is part of a placement or other type of issue, with the proposed issue date being December 22, 2025. The announcement indicates that the company is taking steps to potentially enhance its financial standing and market presence through this securities issuance.
Algorae Pharmaceuticals Limited has announced a proposed issue of securities, specifically options expiring on December 1, 2029. This non-renounceable pro rata issue is set to offer a maximum of 337,678,946 securities, with key dates including an ex-date of November 26, 2025, a record date of November 27, 2025, and an issue date of December 22, 2025. The announcement signifies a strategic move by Algorae Pharmaceuticals to potentially raise capital, which could impact its market positioning and provide stakeholders with investment opportunities.
Algorae Pharmaceuticals Ltd has announced a non-renounceable, pro-rata entitlement offer of ‘Loyalty Options’ to its eligible shareholders. This initiative is designed to acknowledge shareholder support and provide a flexible funding mechanism for future growth. The offer allows shareholders to purchase one Loyalty Option for every five shares held, with the potential to raise approximately $337,679. The Loyalty Options are priced at $0.001 each, exercisable at $0.014, and will expire on December 1, 2029. This move is part of Algorae’s strategy to advance its AI-driven innovation and pharmaceutical commercialization.
Algorae Pharmaceuticals Limited is conducting a non-renounceable pro-rata entitlement offer for up to 337,678,946 Loyalty Options at $0.001 each, available to eligible shareholders on a 1-for-5 basis. This offer, which includes a Shortfall Offer and a Lead Manager Offer, aims to issue new options that can be converted into shares, enhancing shareholder value and potentially impacting market positioning.
Algorae Pharmaceuticals Ltd has launched AlgoraeOS Version 2, a significant upgrade to its AI platform for drug-combination discovery. This new version outperforms state-of-the-art models, providing more reliable predictions for drug synergy, which is expected to enhance the company’s preclinical development pipeline. By integrating biological knowledge with uncertainty-aware deep learning, AlgoraeOS v2 offers a decision-grade tool for prioritizing drug combinations and designing preclinical studies, thus reinforcing Algorae’s leadership in AI-driven therapeutic discovery.
Algorae Pharmaceuticals Limited has issued 1,000,000 fully paid ordinary shares as of November 7, 2025, without disclosure to investors under specific provisions of the Corporations Act 2001. This issuance aligns with regulatory compliance, and the company confirms there is no undisclosed information required under the Act, potentially impacting its market operations and investor relations.
Algorae Pharmaceuticals Limited has announced the issuance of 1,000,000 ordinary fully paid securities under its Employee Incentive Share Plan. This move is part of the company’s strategy to incentivize its employees, potentially impacting its operational dynamics and market positioning by aligning employee interests with shareholder value.
Algorae Pharmaceuticals Ltd has made significant strides in the September 2025 quarter, marked by strategic partnerships and advancements in its AI drug discovery platform. The company executed a licensing agreement with Sakar Healthcare Ltd for five oncology generics and signed a binding term sheet with Cadila Pharmaceuticals Ltd for two generic medicines targeting cardiovascular and metabolic disorders. These partnerships expand Algorae’s commercial portfolio and reinforce its strategy of combining AI-powered drug discovery with pharmaceutical distribution. Additionally, Algorae advanced its proprietary AI platform, AlgoraeOS, and continued pre-clinical development of its therapeutic candidates, AI-116 and AI-168, positioning the company for future growth and innovation in the pharmaceutical industry.
Algorae Pharmaceuticals has entered into a binding term sheet with Cadila Pharmaceuticals to launch two generic medicines in the Australian and New Zealand markets, focusing on cardiovascular and metabolic disorders. This strategic partnership aims to expand Algorae’s commercial footprint and product portfolio through collaboration with Cadila, a major Indian pharmaceutical company. The partnership will formalize through a definitive License and Supply Agreement, after which Algorae will begin planning for Therapeutic Goods Administration registration, impacting its operations and potentially enhancing its industry position.
Algorae Pharmaceuticals has appointed David Gulland as Chief Operating Officer to lead its operational and commercial scale-up initiatives. Gulland’s extensive experience in pharmaceutical operations and leadership in scaling large businesses will be instrumental as Algorae expands its commercial division and AI-driven drug discovery efforts, strengthening its position in the pharmaceutical industry.